Using real-world evidence in haematology.
Best Pract Res Clin Haematol
; 37(1): 101536, 2024 Mar.
Article
en En
| MEDLINE
| ID: mdl-38490764
ABSTRACT
Most new drug approvals are based on data from large randomized clinical trials (RCTs). However, there are sometimes contradictory conclusions from seemingly similar trials and generalizability of conclusions from these trials is limited. These considerations explain, in part, the gap between conclusions from data of RCTs and those from registries termed real world data (RWD). Recently, real-world evidence (RWE) from RWD processed by artificial intelligence has received increasing attention. We describe the potential of using RWD in haematology concluding RWE from RWD may complement data from RCTs to support regulatory decisions.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Aprobación de Drogas
/
Hematología
Límite:
Humans
Idioma:
En
Revista:
Best Pract Res Clin Haematol
Asunto de la revista:
HEMATOLOGIA
Año:
2024
Tipo del documento:
Article
País de afiliación:
Italia